MALVERN, Pa., Feb. 10, 2011 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL), a specialty biopharmaceutical company, today announced financial results for the fourth quarter and the year ended December 31, 2010. The Company also highlighted important commercial, regulatory and clinical development progress during the year 2010 and provided financial and operational guidance for 2011.
For the quarter ended December 31, 2010, Auxilium reported record net revenues of $61.8 million compared to net revenues of $48.0 million in the fourth quarter of 2009, an increase of 29%. For the full year 2010, net revenues totaled $211.4 million compared to net revenues of $164.0 million for the full year 2009, an increase of 29%.
For the quarter ended December 31, 2010, Auxilium reported a net loss of $(16.4) million compared to a net loss of $(11.9) million in the fourth quarter of 2009. For the full year 2010, Auxilium's net loss was $(51.2) million, compared to a net loss of $(53.5) million for the full year 2009.
"In 2010, we believe that Auxilium made good progress toward our vision of becoming a rapidly growing, profitable and sustainable biopharmaceutical company. We achieved record revenues for Testim®, launched XIAFLEX® in the U.S. for Dupuytren's contracture, initiated XIAFLEX global phase III clinical trials for Peyronie's disease and Pfizer, our EU partner, received a positive CHMP opinion for Xiapex® for Dupuytren's contracture," said Armando Anido, Chief Executive Officer and President of Auxilium. "As we look forward to 2011 and beyond, we expect Testim revenues to continue to grow and believe that the potential global market for XIAFLEX represents a blockbuster opportunity, which could provide sustainable long-term growth and pro
|SOURCE Auxilium Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved